Purpose: We hypothesized that SARS-CoV-2 infection numbers reported by governmental institutions are underestimated due to high dark figures as only results from polymerase chain reaction (PCR) tests are incorporated in governmental statistics and testing capacities were further restricted as of July, 2022.
Methods: A point prevalence investigation was piloted by rapid antigen testing (RAT) among participants of the VACCELERATE volunteer registry. 2400 volunteers were contacted, of which 500 received a RAT including instructions for self-testing in the first week of July, 2022. Results were self-reported via e-mail.
Results: 419 valid RAT results were collected until July 7th, 2022. Between July-1 and July-7, 2022, 7/419 (1.67%) tests were positive. Compared to reports of the German Federal Government, our results suggest a more than twofold higher prevalence. Three out of seven positive individuals did not have a PCR test and are therefore likely not to be displayed in governmental statistics.
Conclusion: Our findings imply that the actual prevalence of SARS-CoV-2 may be higher than detected by current surveillance systems, so that current pandemic surveillance and testing strategies may be adapted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590393 | PMC |
| http://dx.doi.org/10.1007/s15010-022-01931-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A modeling study to define guidelines for antigen screening in schools and workplaces to mitigate COVID-19 outbreaks.
Commun Med (Lond)
January 2025
International Research Center for Neurointelligence, The University of Tokyo, Tokyo, Japan.
Background: In-person interaction offers invaluable benefits to people. To guarantee safe in-person activities during a COVID-19 outbreak, effective identification of infectious individuals is essential. In this study, we aim to analyze the impact of screening with antigen tests in schools and workplaces on identifying COVID-19 infections.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
PCM Consulting, Pathways Connectivity Maps Inc., Mountain View, CA, USA.
Background: High-throughput assays have attracted significant attention in Alzheimer's Disease (AD) research, especially for enabling rapid diagnostics screening for factors at the molecular level contributing to the disease recurrence. With advances in laboratory automation, there is a growing need for quality pre-clinical data. Assays such as Microarrays, Proteomics, or AI are all dependent on high-quality input data that serve as a starting point.
View Article and Find Full Text PDFIntroduction: Prostate cancer is incidentally diagnosed in 6%-11% of benign prostatic hyperplasia surgeries.
Case Presentation: A 79-year-old man was diagnosed with benign prostatic hyperplasia. The prostate volume was 54.
Comparison of a Commercial SARS-CoV-2 Rapid Antigen Test with Real-Time PCR.
Infect Dis Clin Microbiol
December 2024
Department of Medical Microbiology, Bursa Uludağ University School of Medicine, Bursa, Türkiye.
Objective: The study compared the mö-screen Corona Antigen Test (Qiagen, Germany) with RT-PCR in suspected COVID-19 patients.
Materials And Methods: Two hundred combined oro-nasopharyngeal swabs were collected from patients with suspected COVID-19 to evaluate the analytical performance of the mö-screen Corona Antigen Test compared to qualitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) in symptomatic patients.
Results: The mö-screen Corona Antigen Test showed an overall agreement with a sensitivity of 100%, a specificity of 100%, a positive predictive value (PPV) of 100%, and a negative predictive value (NPV) of 100%.
Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies.
Theranostics
January 2025
Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, China.
T cell receptor-engineered T (TCR-T) cell therapies are at the forefront of cancer immunotherapy, offering a transformative approach that significantly enhances the ability of T cells to recognize and eliminate cancer cells. This innovative method involves genetically modifying TCRs to increase their affinity for tumor-specific antigens. While these enhancements improve the ability of T cells to recognize and bind to antigens on cancer cells, rigorous assessment of specificity remains crucial to ensure safety and targeted responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!